Explore

Men's Health Recognizes 2026 Health Care Heroes for Pioneering Contributions

Men's Health Recognizes 2026 Health Care Heroes for Pioneering Contributions

Men's Health has announced its 2026 Health Care Heroes, highlighting individuals making significant contributions to the healthcare field. The list includes professionals from various sectors, such as Dr. Ash Tewari, a urologist at Mount Sinai, who has innovated prostate cancer screening through mobile units, and Mike Bonanza, founder of Elevated Access, providing free flights for reproductive and gender-affirming healthcare. Other notable figures include Dr. Ankit Bharat, who performed the first known COVID lung transplant in the U.S., and Jennifer Mensik Kennedy, president of the American Nurses Association, advocating for nurses' professional recognition. These individuals are recognized not only for their groundbreaking work but also for their empathetic and impactful approaches to healthcare.

Abortion pill rulings bring the issue back to the forefront in a midterm election year

Abortion pill rulings bring the issue back to the forefront in a midterm election year

Recent court rulings on abortion pill access have reignited a contentious political issue in a midterm year

Supreme Court Restores Access to Abortion Pill Mifepristone

Supreme Court Restores Access to Abortion Pill Mifepristone

The Supreme Court has restored broad access to the abortion pill mifepristone, allowing it to be distributed through telehealth, mail, and pharmacies. This decision reverses previous restrictions and ensures that mifepristone remains accessible to those seeking medical abortions. The ruling is a significant development in the ongoing debate over reproductive rights and access to healthcare services in the United States.

Justice Alito Temporarily Restores FDA Rule for Mailing Abortion Pill Mifepristone

Justice Alito Temporarily Restores FDA Rule for Mailing Abortion Pill Mifepristone

Justice Samuel Alito has temporarily halted an appellate court order that blocked the FDA's rule allowing the abortion pill mifepristone to be prescribed online and sent by mail. This decision grants temporary relief to Danco Laboratories and GenBioPro, the manufacturers of mifepristone and its generic version, respectively. The stay will remain in place until May 11, giving the Supreme Court time to consider the drug companies' requests to set aside the appellate court's order. The case has brought the issue of mifepristone's availability before the Supreme Court for the second time, following the overturning of Roe v. Wade in 2022.

KFF Report Highlights Medicaid Enrollees Facing Abortion Coverage Restrictions

KFF Report Highlights Medicaid Enrollees Facing Abortion Coverage Restrictions

A recent analysis by the Kaiser Family Foundation (KFF) reveals that nearly half of reproductive-age women enrolled in Medicaid reside in states with restrictive abortion coverage policies. The report indicates that 19% of these women live in states with total abortion bans, while 29% are in states adhering to Hyde Amendment restrictions, which prohibit federal funding for abortions except in cases of rape, incest, or life endangerment. Despite the overturning of Roe v. Wade in 2022, five states have removed Medicaid abortion coverage restrictions, and 21 states use state-only funds for Medicaid abortions beyond Hyde limitations. The report also notes that 25 states continue to ban abortion coverage in Affordable Care Act (ACA) Marketplace plans, leaving individuals in 31 states without access to plans covering abortions.

Supreme Court Asked to Intervene in Abortion Pill Access Dispute

Supreme Court Asked to Intervene in Abortion Pill Access Dispute

The manufacturers of the abortion pill mifepristone have appealed to the Supreme Court following a lower court's decision to restrict access to the drug. Previously available through mail and telehealth, the pill's accessibility has been limited, prompting legal action. This development is part of an ongoing legal battle over reproductive rights and access to abortion services in the United States.

Supreme Court Temporarily Restores Mail Access to Abortion Pill Amid Legal Battle

Supreme Court Temporarily Restores Mail Access to Abortion Pill Amid Legal Battle

The U.S. Supreme Court has temporarily paused a lower court ruling that restricted the mailing of the abortion pill mifepristone, allowing patients to continue receiving it by mail. This decision comes after the 5th U.S. Court of Appeals ruled to require in-person visits for obtaining the pill, a move that was challenged by the drug's manufacturers, Danco Laboratories LLC and GenBioPro Inc. Justice Samuel Alito issued the administrative stay, which is in effect until May 11, providing the court more time to consider the implications of the appellate ruling. The case has sparked significant debate, with reproductive rights advocates viewing the stay as a temporary relief, while anti-abortion groups express disappointment.

Supreme Court Restores Broad Access to Abortion Pill Mifepristone via Telehealth and Pharmacies

Supreme Court Restores Broad Access to Abortion Pill Mifepristone via Telehealth and Pharmacies

The Supreme Court has reinstated broad access to the abortion pill mifepristone, allowing it to be distributed through telehealth services, mail, and pharmacies. This decision reverses previous restrictions that limited the availability of the medication, which is commonly used in medical abortions. The ruling is significant as it ensures that individuals seeking an abortion can access mifepristone without the need for in-person visits to healthcare providers, thereby expanding the reach of reproductive healthcare services.

Federal Appeals Court Restricts Telemedicine Access to Mifepristone, Misoprostol Remains Available

Federal Appeals Court Restricts Telemedicine Access to Mifepristone, Misoprostol Remains Available

A recent ruling by a federal appeals court has reinstated in-person prescribing requirements for mifepristone, a drug commonly used in medication abortions in the United States. This decision reverses the previous FDA policy under President Joe Biden, which allowed the drug to be prescribed via telemedicine and mailed to patients. The ruling affects the entire country, although the manufacturers of mifepristone have appealed to the Supreme Court to revert to the previous telemedicine-friendly rules. In the meantime, misoprostol, the second drug in the typical two-drug abortion regimen, remains available and can be used alone for medication abortions. Misoprostol is also used for other medical purposes, such as treating gastric ulcers and managing miscarriages. While the misoprostol-only protocol is effective, it tends to cause more side effects compared to the two-drug regimen.

US Supreme Court lets abortion pill mail delivery restart for now

US Supreme Court lets abortion pill mail delivery restart for now

By Andrew Chung May 4 (Reuters) - The U.S.

Supreme Court Petitioned in Abortion Pill Access Dispute

Supreme Court Petitioned in Abortion Pill Access Dispute

The manufacturers of the abortion pill mifepristone have appealed to the Supreme Court following a lower court's decision to restrict access to the drug. Previously, mifepristone was available through mail or telehealth services, but the recent ruling has limited these options. This legal battle highlights ongoing tensions surrounding reproductive rights and access to abortion services in the United States. The case has drawn significant attention as it could set a precedent for how abortion-related medications are regulated and accessed nationwide.

Supreme Court Temporarily Restores Access to Abortion Pill Mifepristone Amid Legal Disputes

Supreme Court Temporarily Restores Access to Abortion Pill Mifepristone Amid Legal Disputes

The Supreme Court has issued a temporary order to maintain broad access to the abortion pill mifepristone, countering recent lower-court restrictions. Justice Samuel Alito signed the order, which allows the continuation of federal rules permitting the drug's distribution through pharmacies and mail without requiring an in-person doctor visit. This decision comes as the court considers emergency appeals from mifepristone manufacturers, who are challenging the restrictions imposed by a federal appeals court. Mifepristone, used in combination with misoprostol, accounts for the majority of medication abortions in the U.S. The availability of these pills has been crucial in states with abortion bans following the Supreme Court's 2022 decision to overturn Roe v. Wade. The order will remain effective for at least another week while further filings are submitted.